Parexel has introduced ParexelAI, an innovative, proprietary suite of human-led AI services and capabilities that power Parexel operations and deliver greater speed, quality and efficiency to customers and, ultimately, patients.

ParexelAI unifies and leverages the company's full suite of AI capabilities with human oversight and transparency built into every stage. With proprietary tools deployed across the entire clinical development lifecycle, from early phase through post-market surveillance, and drawing on a diverse mix of internal innovation, strategic collaborations, and best-in-class external capabilities, ParexelAI delivers measurable impact for sponsors, research sites and patients.

Peyton Howell, Chief Executive Officer (CEO), Parexel, said, “ParexelAI represents years of deep technology integration, all in service of helping our customers deliver life-changing treatments to patients. We have a responsibility to continually evolve by advancing our capabilities, strengthening our partnerships and innovating in ways that help sponsors run faster, more effective trials. ParexelAI is a natural extension of our corporate growth strategy and our commitment to meeting our customers’ current and future needs with confidence.”

Through its recent acquisition of Vitrana, Parexel can also now provide a fully integrated pharmacovigilance (PV) platform that leverages intelligent automation and AI to accelerate end-to-end Patient Safety and PV processes, deliver first-time quality and enhance compliance.

Rob Goodwin, Chief Operating Officer (COO), Parexel, said, “Our tools are designed to automate previously manual work that slows teams down, enabling our experts to increase quality and consistency, surface even more insights for our customers and further improve operational excellence. Supporting our customers at every stage of drug development means they can leverage AI benefits across every aspect of their program, not just in siloed areas.”

ParexelAI prioritises human judgment, scientific and regulatory expertise, patient safety, and ethical accountability at the center of every AI solution. It automates repetitive tasks, empowering Parexel’s 22,000+ global experts–including PhDs in Machine Learning (ML), world-leading regulatory experts, seasoned clinical operations leaders and technology specialists–to focus on strategic guidance, problem-solving and other high-impact challenges that clinical development demands.

Tala Fakhouri, PhD, MPH, Chief AI & Regulatory Strategy Officer, Parexel, said, “AI delivers its greatest value when it amplifies human expertise. Our human-in-the-lead model ensures quality, compliance and patient safety at every stage of the trial lifecycle. With ParexelAI, we’re able to apply these insights in real-time to improve every trial. Every efficiency gained and every workflow accelerated serves a single purpose, getting treatments to patients sooner.”